| mRNA |
Gemcitabine |
gCSI |
pan-cancer |
AAC |
-0.011 |
0.9 |
| mRNA |
trifluoperazine |
CTRPv2 |
pan-cancer |
AAC |
0.0072 |
0.9 |
| mRNA |
PF-573228 |
CTRPv2 |
pan-cancer |
AAC |
0.0063 |
0.9 |
| mRNA |
FMK |
GDSC1000 |
pan-cancer |
AAC |
-0.0069 |
0.9 |
| mRNA |
BRD-K51490254 |
CTRPv2 |
pan-cancer |
AAC |
-0.0067 |
0.9 |
| mRNA |
BRD-K02251932 |
CTRPv2 |
pan-cancer |
AAC |
0.0069 |
0.9 |
| mRNA |
ML334 diastereomer |
CTRPv2 |
pan-cancer |
AAC |
-0.0079 |
0.9 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0066 |
0.9 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0062 |
0.9 |
| mRNA |
QS11 |
GDSC1000 |
pan-cancer |
AAC |
-0.0062 |
0.9 |